Concepedia

Publication | Open Access

A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer

DOIFull Paper Access

36

Citations

34

References

2018

Year

Fang Zhao, Ekaterina Olkhov‐Mitsel, Shivani Kamdar, Renu Jeyapala, Julia Garcia, Rachel Hurst, Marcelino Yazbek Hanna, Robert Mills, Alexandra V. Tuzova, Eve O’Reilly,
Clinical Epigenetics

Abstract

ProCUrE is a promising non-invasive urinary methylation assay for the early detection and prognostication of prostate cancer. ProCUrE has the potential to supplement PSA testing to identify patients with clinically significant prostate cancer.

References

YearCitations

Page 1